Keensight Capital’s Acquisition of Inke

Clifford Chance has advised Neuraxpharm on the deal. Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announced...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Permira’s Acquisition of Neuraxpharm

Clifford Chance advised Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders on the sale of Spanish pharmaceutical...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

EQT’s EUR 881 Million Voluntary Takeover Bid Over Solarpack Corporación Tecnológica, S.A.

Clifford Chance advised EQT on the deal. Cuatrecasas advised the selling shareholders. Solarpack is a multinational specialized in the development, financing, construction, operation and management of utility...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here